Helius Medical Technologies, Inc. a neurotech company focused on neurological wellness, today announced that the Company has entered into an agreement with HealthTech Connex, Inc. (“HTC”) to develop and manage neuroplasticity clinics in Canada.

“We are excited to announce this strategic alliance with HealthTech Connex and look forward to establishing our commercial infrastructure in Canada,” said CEO Philippe Deschamps. “This new agreement with HTC will result in the formation of a new operating entity called Heuro Canada and is the first step towards our shared goal of giving hope to people with Traumatic Brain Injury by ensuring that our novel therapy will be accessible to Canadians once cleared by the regulatory authorities.”

“The agreement to establish Heuro Canada is an important step in establishing the commercial infrastructure for both the PoNS™ Treatment and the NeuroCatch™ Platform measurement in Canada,” said Kirk Fisher, CEO of HealthTech Connex. “Heuro Canada will establish two neuroplasticity clinics here in Canada, initially, as we consider future expansion.  We look forward to the possibility of expanding our commercial infrastructure through the newly formed Heuro Canada venture.”

Both the Portable Neuromodulation Stimulator (PoNS™) device and the NeuroCatch™ Platform are currently investigational devices, not for sale in Canada or the US.  PoNS was submitted for review by Health Canada on September 27th, 2018 and the NeuroCatch™ Platform is planned to be submitted to Health Canada in Q1 of 2019.  Both technologies will be used in Heuro Canada neuroplasticity clinics only if and when those technologies are cleared for use in Canada by Health Canada. Subject to the foregoing, Heuro Canada is anticipated to be operational in the fourth quarter of 2018.